MedTrace Logo

Pravastatin for Hyperlipidaemia in HIV.

NCT00227500 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2006-06-09

No results posted yet for this study

Summary

This study is a randomised, placebo-controlled study of the effect of treatment with the HMG-CoA reductase inhibitor, pravastatin, in HIV-infected, protease inhibitor treated patients with high serum cholesterol. We hypothesise that pravastatin will result in greater reductions in cholesterol than placebo when used in conjunction with appropriate dietary advice.

Conditions

  • HIV Infections
  • Lipid Metabolism
  • Glucose Metabolism
  • Metabolic Abnormality
  • Lipodystrophy
  • Cardiovascular Disease

Interventions

DRUG

Pravastatin

Sponsors & Collaborators

  • The University of New South Wales

    collaborator OTHER

  • National Heart, Lung, and Blood Institute (NHLBI)

    collaborator NIH

  • Garvan Institute of Medical Research

    collaborator OTHER

  • St Vincent's Hospital, Sydney

    collaborator OTHER

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Andrew D Carr, MD · National Centre in HIV Epidemiology and Clinical Research.

  • David A Cooper, MD · National Centre in HIV Epidemiology and Clinical Research.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-31
Completion
2004-10-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00227500 on ClinicalTrials.gov